Delivery Order SPE2DB22D1106-SPE2DB25FEKU9
Award Date
4/28/25
Potential Completion Date
4/29/25
Potential Value
$32K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, with ID SPE2DB22D2007|SPE2DB25FJ1CR, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,491.63 delivery order contract is for the supply of the pharmaceutical product Exforge 5-160 mg tablet, with a performance period through May 1, 2025. Amerisourcebergen Drug Corp holds a substantial $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award, valued at $7,932.90, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order contract for the supply of Exforge 10-160 mg tablets, a medication used to treat high blood pressure. The contract has a firm fixed price and an ultimate completion date of May 6, 2025. This award is not set aside and is part of a larger Indefinite Delivery Contract...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,042.14 firm fixed-price delivery order is for the supply of Exforge 5-160 mg tablets, a medication used to treat high blood pressure. The contract has an ultimate completion date of December 8, 2022 and was awarded on December 7, 2022. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery...
This federal contract award, identified as SPE2DB22D2006|SPE2DB25FW0JC, was granted by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Exforge 5-160 mg tablets, a medication used to treat high blood pressure. The contract is a Firm Fixed Price Delivery Order with a ceiling value of $4,969.32 and an ultimate completion date of April 29, 2025. The contract is not set aside...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,258.65 firm fixed-price delivery order (SPE2DB20D3101|SPE2DB23FQUV5) is for 30-count packages of the medication Exforge HCT 10-320-25 mg tablets. The contract has an ultimate completion date of November 16, 2022. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award is to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Exforge 10-320 mg tablets in support of the Medical Supply Chain program at the Defense Logistics Agency (DLA). The contract has a ceiling value of $11,592.55 and an ultimate completion date of May 19, 2023. It is a firm fixed-price delivery order contract with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc.,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $1,262.36, is a Delivery Order contract for the supply of Exforge HCT 10-160-12.5 mg tablets. The contract has an ultimate completion date of November 20, 2024 and is a Firm Fixed Price (FFP) arrangement. This award does not have a set-aside designation, indicating open competition....
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,570.80, is a delivery order for Exforge 10-320 mg tablets, with an ultimate completion date of April 10, 2025. The contract is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November...
This federal contract award, with ID SPE2DB22D2009|SPE2DB24FM0YE, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,481.36 firm fixed-price contract is for the delivery of Exforge 10-320 mg tablets. The contract is not designated under any set-aside program. It is a delivery order awarded under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen...
This federal contract award, with ID SPE2DB20D2104|SPE2DB21FT94F, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $2,996.86 firm fixed-price delivery order covers the supply of Exforge HCT 10-320-25 mg tablets to support the DLA's medical requirements. Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through...